AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1941495 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse used as an adjunct to oral hygiene before toothbrushing
Number of subjects: 0
Study 6108262 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine maleate/pseudoephedrine sulfate
Number of subjects: 0
Study 6108262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30845047 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT + RT
Number of subjects: 22
Study 30845047 — intervention group
Group type: COMPARATOR
Intervention: TRT
Number of subjects: 22
Study 30845047 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TRT and TRT + RT)
Number of subjects: 22
Study 28893633 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 224
Study 28893633 — intervention group
Group type: COMPARATOR
Intervention: Open donor nephrectomy
Number of subjects: 224
Study 25809373 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg for 3 months or 30 mg with increased exposure factors) + Aspirin (100 mg/d for 6 months)
Number of subjects: 203
Study 25809373 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d for 3 months) + Aspirin (100 mg/d for 6 months)
Number of subjects: 203
Study 24010849 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Group (SG) - hemodynamic therapy guided by pulse pressure variation, cardiac index trending, and mean arterial pressure.
Number of subjects: 160
Study 24010849 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - hemodynamic therapy at the discretion of the treating anesthesiologist.
Number of subjects: 160
Study 24010849 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Group (SG)
Number of subjects: 160
Study 24010849 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 160
Study 21504240 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol added to tiotropium (Symbicort® Turbuhaler® 320/9 μg twice daily + tiotropium 18 μg daily)
Number of subjects: 659
Study 21504240 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to tiotropium (tiotropium 18 μg daily)
Number of subjects: 659
Study 21504240 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol added to tiotropium
Number of subjects: 659
Study 19339010 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-contrast sonography (HyCoSy)
Number of subjects: 88
Study 19339010 — intervention group
Group type: COMPARATOR
Intervention: Radiographic hysterosalpingography (HSG)
Number of subjects: 88
Study 16455835 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 35
Study 16455835 — intervention group
Group type: COMPARATOR
Intervention: Sham-placebo (subtherapeutic CPAP)
Number of subjects: 35
Study 14665547 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 40
Study 14665547 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study 11544424 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (Zenapax®, Roche Pharmaceuticals)
Number of subjects: 0
Study 11544424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9175060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cannulation
Number of subjects: 66
Study 9175060 — intervention group
Group type: COMPARATOR
Intervention: External landmark-guided technique
Number of subjects: 66
Study 8433235 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin-containing oral rehydration solution
Number of subjects: 120
Study 8433235 — intervention group
Group type: COMPARATOR
Intervention: Standard recommended glucose
Number of subjects: 120
Study 2891522 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH treatment
Number of subjects: 60
Study 2891522 — intervention group
Group type: COMPARATOR
Intervention: Surgery (control)
Number of subjects: 60
Study 29701044 — intervention group
Group type: EXPERIMENTAL
Intervention: Special penetration needling
Number of subjects: 97
Study 29701044 — intervention group
Group type: COMPARATOR
Intervention: Conventional penetration needling
Number of subjects: 97
Study 26995053 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 2198
Study 26995053 — intervention group
Group type: COMPARATOR
Intervention: No bleed
Number of subjects: 2198
Study 26995053 — intervention group
Group type: COMPARATOR
Intervention: Access site bleeds (ASB)
Number of subjects: 2198
Study 26995053 — intervention group
Group type: COMPARATOR
Intervention: Rest of bleeds (ROB)
Number of subjects: 2198
Study 25335387 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium deficiency correction
Number of subjects: 0
Study 25335387 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy without magnesium deficiency correction
Number of subjects: 0
Study 23720246 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (ibuprofen sustained-release)
Number of subjects: 19
Study 23720246 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (ibuprofen sustained-release)
Number of subjects: 19
Study 20873912 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 120
Study 18773807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-graft group (posterior lumbar interbody fusion with autologous iliac crest)
Number of subjects: 60
Study 18773807 — intervention group
Group type: COMPARATOR
Intervention: Cage group (posterior lumbar interbody fusion with interbody fusion cage)
Number of subjects: 60
Study 18773807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-graft group
Number of subjects: 60
Study 18773807 — intervention group
Group type: COMPARATOR
Intervention: Cage group
Number of subjects: 60
Study 18773807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 15696568 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise classes
Number of subjects: 300
Study 15696568 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 14598996 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexican American version of the curriculum
Number of subjects: 6035
Study 14598996 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicultural version of the curriculum
Number of subjects: 6035
Study 14598996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined African American and European American version of the curriculum
Number of subjects: 6035
Study 14598996 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6035
Study 10499756 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (30 microg/kg followed by 3 microg/kg/h for 3 days)
Number of subjects: 27
Study 10499756 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (0.05-0.1 mg/kg intraoperatively, followed by 0.02 mg/kg doses postoperatively)
Number of subjects: 27
Study 10499756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Epidural and Intravenous)
Number of subjects: 27
Study 8560681 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg monotherapy
Number of subjects: 3000
Study 8560681 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg plus LHRH-A
Number of subjects: 3000
Study 8560681 — intervention group
Group type: COMPARATOR
Intervention: Flutamide plus LHRH-A
Number of subjects: 3000
Study 8560681 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 3000
Study 1298575 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational, low‐fear intervention (pictorial diagram of periodontal disease and discussion of flossing importance)
Number of subjects: 41
Study 1298575 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief dental examination and flossing instruction)
Number of subjects: 41
Study 6428655 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (videotape)
Number of subjects: 25
Study 6428655 — intervention group
Group type: COMPARATOR
Intervention: Personal group (personal teaching)
Number of subjects: 25
Study 31012040 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen (800 mg)
Number of subjects: 90
Study 31012040 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen (1000 mg)
Number of subjects: 90
Study 31012040 — intervention group
Group type: COMPARATOR
Intervention: Control (100 ml saline solution)
Number of subjects: 90
Study 31442441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic-acid-containing diaphragm gel (Contragel®)
Number of subjects: 23
Study 31442441 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethylcellulose (HEC) universal placebo gel
Number of subjects: 23
Study 28363270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling
Number of subjects: 0
Study 28363270 — intervention group
Group type: COMPARATOR
Intervention: Cortisone Injections
Number of subjects: 0
Study 25361992 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 938
Study 25361992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 938
Study 25361992 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 938
Study 24014057 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 44
Study 24014057 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 44
Study 21844156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of grade 1 CFAE
Number of subjects: 20
Study 21844156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of grade 2 CFAE
Number of subjects: 20
Study 21844156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of grade 3 CFAE
Number of subjects: 20
Study 21844156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of grade 4 CFAE
Number of subjects: 20
Study 21844156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of grade 5 CFAE
Number of subjects: 20
Study 19643636 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided biopsy with i.v. contrast application following needle placement (group 1)
Number of subjects: 60
Study 19643636 — intervention group
Group type: COMPARATOR
Intervention: CT-guided biopsy after contrast enhanced CT (group 2)
Number of subjects: 60
Study 19643636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 60
Study 16632812 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon inflation
Number of subjects: 75
Study 16632812 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction (pressing a rubber ball)
Number of subjects: 75
Study 16632812 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 75
Study 12560782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once a day
Number of subjects: 633
Study 12560782 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam 3.375 g every 6 hours
Number of subjects: 633
Study 11256724 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 163
Study 11256724 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 163
Study 11256724 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT (staffed by consumers or non-consumers)
Number of subjects: 163
Study 8807592 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) 5 mg/day s.c during treatment period (Tx) for 7 days
Number of subjects: 10
Study 8807592 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment period (PostGH) after discontinuation of rhGH
Number of subjects: 10
Study 1522292 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide and oxygen
Number of subjects: 20
Study 1522292 — intervention group
Group type: COMPARATOR
Intervention: Oxygen placebo
Number of subjects: 20
Study 6094868 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT/CPZ at 20 mg/kg
Number of subjects: 43
Study 6094868 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT/CPZ at 40 mg/kg
Number of subjects: 43
Study 30325529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol for four days
Number of subjects: 48
Study 30325529 — intervention group
Group type: COMPARATOR
Intervention: Placebo for four days
Number of subjects: 48
Study 30325529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 48
Study 29924745 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TEX, 100 mg·wk)
Number of subjects: 3
Study 29924745 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (PEX)
Number of subjects: 3
Study 29924745 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 3
Study 26432791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pavlik harness treatment (group I: start within 10 days, group II: 11 days to 3 weeks, group III: after 4 weeks)
Number of subjects: 62
Study 25175668 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlong Active stem
Number of subjects: 50
Study 25175668 — intervention group
Group type: COMPARATOR
Intervention: Furlong HAC stem
Number of subjects: 50
Study 25175668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stem types
Number of subjects: 50
Study 22475493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 385
Study 22475493 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 385
Study 20643822 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle sparing thoracotomy (MST)
Number of subjects: 100
Study 20643822 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral thoracotomy (PLT)
Number of subjects: 100
Study 17269287 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16235185 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplification of pfmdr1 in patient samples from 1995
Number of subjects: 0
Study 16235185 — intervention group
Group type: COMPARATOR
Intervention: Samples collected in 2002
Number of subjects: 0
Study 12120848 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led sex education
Number of subjects: 505
Study 10378663 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialysis membranes
Number of subjects: 660
Study 10378663 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialysis membranes
Number of subjects: 660
Study 7767393 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 250iu of anti-D Ig given at 28 and 34 weeks gestation
Number of subjects: 1108
Study 7767393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1108
Study 2310093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride inhalation (10(‐3) M)
Number of subjects: 23
Study 2310093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride inhalation (2 times a day for 3 weeks)
Number of subjects: 23
Study 2310093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride inhalation
Number of subjects: 23
Study 2310093 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 23
Study 466843 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (n = 8)
Number of subjects: 18
Study 466843 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group (n = 10)
Number of subjects: 18
Study 466843 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 18
Study 466843 — intervention group
Group type: COMPARATOR
Intervention: Acrophobic patients (n = 18)
Number of subjects: 18
Study 31761434 — intervention group
Group type: EXPERIMENTAL
Intervention: Moment feedback
Number of subjects: 97
Study 31761434 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk inclination angle feedback
Number of subjects: 97
Study 31761434 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar flexion feedback
Number of subjects: 97
Study 31761434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 97
Study 30327949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental nerve block
Number of subjects: 30
Study 30327949 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraorbital nerve block
Number of subjects: 30
Study 30327949 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study 28416849 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cleaning of tongue coating
Number of subjects: 10
Study 28416849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction for cleaning)
Number of subjects: 10
Study 25994910 — intervention group
Group type: COMPARATOR
Intervention: Standard BFM therapy
Number of subjects: 291
Study 25994910 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended, usually more intensive experimental treatment
Number of subjects: 291
Study 24242264 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLVE intervention
Number of subjects: 921
Study 24242264 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 921
Study 21957625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexam
Number of subjects: 78
Study 21957625 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 19048458 — intervention group
Group type: EXPERIMENTAL
Intervention: benzbromarone
Number of subjects: 69
Study 19048458 — intervention group
Group type: COMPARATOR
Intervention: allopurinol
Number of subjects: 69
Study 19048458 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 69
Study 19048458 — intervention group
Group type: COMPARATOR
Intervention: uric acid
Number of subjects: 69
Study 19048458 — intervention group
Group type: EXPERIMENTAL
Intervention: GW9662 (PPARgamma antagonist) with benzbromarone
Number of subjects: 69
Study 19048458 — intervention group
Group type: EXPERIMENTAL
Intervention: GW9662 (PPARgamma antagonist) with pioglitazone
Number of subjects: 69
Study 16889452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 24
Study 16889452 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit Reversal Training (HRT)
Number of subjects: 24
Study 16889452 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Sertraline and HRT
Number of subjects: 24
Study 16889452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11908535 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-training program
Number of subjects: 0
Study 11908535 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 11715490 — intervention group
Group type: EXPERIMENTAL
Intervention: E1 group (esmolol 1 mg/kg)
Number of subjects: 1830
Study 11715490 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 group (esmolol 2 mg/kg)
Number of subjects: 1830
Study 11715490 — intervention group
Group type: COMPARATOR
Intervention: E0 group (0.9% NaCl)
Number of subjects: 1830
Study 7499516 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous extraction catheter (TEC) atherectomy device (2.7 mm, 4.0 mm, or 4.7 mm) followed by balloon dilatation
Number of subjects: 0
Study 7499516 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilatation alone
Number of subjects: 0
Study 2309541 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg/kg rectally as premedication
Number of subjects: 20
Study 2309541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no midazolam)
Number of subjects: 20
Study 445714 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 20
Study 445714 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 31961238 — intervention group
Group type: EXPERIMENTAL
Intervention: Packing with gelatin sponge
Number of subjects: 36
Study 31961238 — intervention group
Group type: COMPARATOR
Intervention: Packing with nothing
Number of subjects: 36
Study 29525478 — intervention group
Group type: EXPERIMENTAL
Intervention: 2015 guidelines with feedback/prompt device (2015F)
Number of subjects: 124
Study 29525478 — intervention group
Group type: COMPARATOR
Intervention: 2015 guidelines without feedback
Number of subjects: 124
Study 29525478 — intervention group
Group type: COMPARATOR
Intervention: 2010 guidelines
Number of subjects: 124
Study 26990304 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg IV)
Number of subjects: 23
Study 26990304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 23
Study 26246241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU followed by 4,000 IU daily for 16 weeks)
Number of subjects: 50
Study 26246241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules for 16 weeks)
Number of subjects: 50
Study 26246241 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 50
Study 26246241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23394604 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 50
Study 23394604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20577225 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lactalbumin (αlac)
Number of subjects: 87
Study 20577225 — intervention group
Group type: COMPARATOR
Intervention: Sustained milk protein (SP)
Number of subjects: 87
Study 20577225 — intervention group
Group type: COMPARATOR
Intervention: Supra sustained milk protein (SSP)
Number of subjects: 87
Study 20577225 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (αlac, SSP, SP)
Number of subjects: 87
Study 18563688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with pemetrexed and cisplatin
Number of subjects: 0
Study 18563688 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in pretreated patients
Number of subjects: 0
Study 18563688 — intervention group
Group type: COMPARATOR
Intervention: Targeted therapies
Number of subjects: 0
Study 16630771 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg 3 times daily for 6 months)
Number of subjects: 52
Study 12649866 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion titrated to a Bispectral Index near 80
Number of subjects: 8